NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

FASENRA SCEI for Long-term Use

CompletedN/A

Sponsor: AstraZeneca

Conditions: Asthma

Countries: Japan

The purpose of the investigation is to confirm the safety and efficacy under the post-marketing actual long-term use of FASENRA Subcutaneous Injection 30 mg Syringe.

Eligibility overview

Sex: ALL

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

-The evaluable patients treated with Fasenra for the first time due to "Bronchial asthma (only the patients with intractable bronchial asthma which could not be controlled with the existing therapy).

Exclusion Criteria:

-No past history of hypersensitivity to the components of Fasenra.

Locations (29)

Aichi, Japan
Akita, Japan
Aomori, Japan
Chiba, Japan
Ehime, Japan
Fukuoka, Japan
Gunma, Japan
Hiroshima, Japan
Hokkaido, Japan
Hyōgo, Japan
Ibaraki, Japan
Kagawa, Japan
Kagoshima, Japan
Kanagawa, Japan
Kumamoto, Japan
Kyoto, Japan
Mie, Japan
Miyagi, Japan
Numakunai, Japan
Okayama, Japan
Okinawa, Japan
Osaka, Japan
Ōita, Japan
Saitama, Japan
Shiga, Japan
Tochigi, Japan
Tokyo, Japan
Yamagata, Japan
Yamaguchi, Japan